



– Introducing Cool-B70 A/P

For advanced double-blinded research studies

- Active and placebo stimulation combined in one coil
- No indication of which side is active and which is placebo
- Active liquid cooling allows for running demanding research protocols
- Advanced research software supports double-blinded studies



Why choose Cool-B70 A/P?


The Cool-B70 A/P coil has been designed for advanced research studies.

Symmetrical design with no indication of active and placebo side allows for true double-blinded research.

Create skin-sensation of real stimulation even when the coil is placed in placebo position.

Built-in orientation switch determines which side of the coil should be placed toward the research subject.

Compatible with lightweight MT coil C-B70.



Technical data

Dimensions		Coil Winding Data		Ordering Number	
Weight of transducer head:	2.5 kg / 5.5 lbs	Inner diameter:	27 mm / 1.1 in.	Cool-B70 A/P	9016E0121
Transducer head dimensions:	173x116x80/114 mm 6.8x4.6x3.1/4.5 in.	Outer diameter:	97 mm / 3.8 in.		
Angle:	150°	Winding height:	6 mm / 0.2 in.		
Cable length:	2 m / 6.6 ft.	Number of windings:	2 x 10		

All products are developed and manufactured in accordance with the standard ISO 13485:2012, the current EU Medical Device Directive, the Canadian Medical Devices Regulation (CMDR), US 21 CFR 820 for the USA, and in accordance with a number of additional country-specific regulations.

MagPro stimulators and coils are approved as medical devices in Europe, the USA, Canada, China, Japan, South Korea, Australia, Russia, and other markets worldwide.

MagPro®, MagVenture TMS Therapy® and MagVenture® are registered trademarks of MagVenture A/S.

Please note that not all stimulators, coils, and accessories are cleared for sale in the USA by the Food and Drug Administration (FDA). Please also note that in the USA Transcranial Magnetic Stimulation is considered investigational - except for the cleared intended use for treatment of Major Depressive Disorder in adult patients who have failed to receive satisfactory improvement from prior antidepressant medication in the current episode.

More info at

www.magventure.com

MagVenture
Research. Treatment. Results.